Infections

All Conditions

Symptoms and General Pathology

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Communicable Diseases

Papillomavirus Infections

Disease Attributes

Sexually Transmitted Diseases

Sexually Transmitted Diseases, Viral

Virus Diseases

DNA Virus Infections

Tumor Virus Infections

Genital Diseases

Urogenital Diseases

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Interferons

Interferon-alpha

Interferon alpha-2

Antiviral Agents

subject were treated with Yallaferon®， the recombinant human interferon α-2b gel

Yallaferon®

to assess the efficacy and safety of recombinant human interferon α-2b gel (Yallaferon®) for the treatment of patients with cervical high-risk HPV infections; to analyze the HPV type infections and clinical negative conversion.

285 patients with positive high risk HPV infection were randomized into interferon gel group and control group at ratio of 2:1 (203 patients in treatment group and 82 patients in control group). The patients in treatment group received 1g recombinant human α-2b interferon gel every other day for consecutive 3 courses of treatment, whereas no treatment was conducted in control group.

Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections

a Multi-sites, Randomized, Parallel, Controlled Clinical Study to Evaluated the Efficacy and Safety of Recombinant Human Interferon Alpha-2b Gel (Yallaferon®) in HPV Infection

Primary efficacy endpoint was the difference of hr-HPV DNA negative conversion rate on the 6th month between the two groups.

Secondary efficacy endpoints were the differences of single-type HPV infection, dual infection and multiple infections on the 6th month between the two groups.

Evaluation criteria:

Negative conversion was defined as all positive hr-HPV DNA at baseline turning negative.

Non-negative conversion was defined as at least one of the positive hr-HPV DNA at baseline not turning negative.

Lee's Pharmaceutical Limited

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections	NCT01824992	HPV Infection	Yallaferon®	30 Years - 65 Years	Lee's Pharmaceutical Limited
Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections	NCT01824992	HPV Infection	Yallaferon®	30 Years - 65 Years	Lee's Pharmaceutical Limited

Spots Global Cancer Trial Database for yallaferon®

Every month we try and update this database with for yallaferon® cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.